Bextra Meta-Analysis Affirms Safety Profile, Pfizer Tells Physicians
Executive Summary
A meta-analysis of Bextra (valdecoxib) clinical trials in osteoarthritis and rheumatoid arthritis show the agent has a lower incidence of myocardial infarctions compared to traditional NSAIDs, Pfizer maintains in Dec. 2 "medical information letters.
You may also be interested in...
Mobic Adds Juvenile RA Indication, Cardiovascular “Black Box” Warnings
Addition of a juvenile rheumatoid arthritis indication to Boehringer Ingelheim's Mobic provided an opportunity to add class cardiovascular and gastrointestinal risk language to labeling for the nonsteroidal anti-inflammatory drug
Mobic Adds Juvenile RA Indication, Cardiovascular “Black Box” Warnings
Addition of a juvenile rheumatoid arthritis indication to Boehringer Ingelheim's Mobic provided an opportunity to add class cardiovascular and gastrointestinal risk language to labeling for the nonsteroidal anti-inflammatory drug
Pfizer Celebrex Revised Labeling Adds Class Cardio Risk, Moves Safety Data
Pfizer appears to have used the relabeling of its COX-2 inhibitor Celebrex to add class cardiovascular risk language as an opportunity to renegotiate the placement of safety data